Liposomal Vitamin D3 compared with Calcidiol(Calcifediol)

Executive Summary

Perplexity AI Jan 2025

Liposomal vitamin D3 and calcidiol (25-hydroxyvitamin D3, also known as calcifediol) represent two distinct advanced approaches to vitamin D supplementation, each addressing different limitations of traditional cholecalciferol formulations. Liposomal vitamin D3 leverages nanoscale delivery technology to enhance absorption and bioavailability of cholecalciferol, while calcidiol bypasses hepatic metabolism by providing the direct metabolic precursor to active vitamin D. This analysis synthesizes clinical evidence, pharmacological mechanisms, and practical considerations to guide selection between these formulations across different clinical scenarios.

Key Distinctions:

Parameter Liposomal Vitamin D3 Calcidiol
Chemical form Cholecalciferol (vitamin D3) in lipid vesicles 25-hydroxyvitamin D3
Absorption mechanism Enhanced via endocytosis/transcytosis Direct intestinal absorption, more hydrophilic
Hepatic metabolism required Yes No (already hydroxylated)
Potency vs. cholecalciferol 4-5× higher bioavailability[1][2] 3-8× more potent per microgram[3][4][5]
Onset of action Rapid (hours)[1][6][2] Very rapid (days)[3][7][8]
Regulatory status Dietary supplement Prescription drug (Rayaldee®) for CKD; supplement in some countries[9][10]
Cost Moderate (consumer supplement pricing)[11][12][13] High (prescription: ~$1,180/month)[14]

Pharmacological Mechanisms and Absorption

Liposomal Vitamin D3: Advanced Delivery Technology

Liposomal formulations encapsulate cholecalciferol within nanoscale lipid vesicles (typically 100-120 nm), fundamentally altering absorption kinetics compared to traditional oil-based supplements.[1][2]

Absorption Pathway: Vitamin D3 (logP >7) is exceptionally hydrophobic, requiring lipid carriers for absorption. In conventional oily formulations, cholecalciferol forms heterogeneous, unstable emulsions in the gastrointestinal tract that are prone to coalescence, resulting in unpredictable particle sizes often exceeding 400 nm—too large to efficiently penetrate the intestinal mucus barrier. Liposomal technology addresses these limitations through:[2][1]

  1. Mucus Penetration: Uniform liposomes (<300 nm) readily traverse the polymeric mucin mesh lining the intestinal epithelium, which acts as a size-exclusion filter.[1][2]

  2. Cellular Uptake: Enterocytes and M cells internalize intact liposomes via endocytosis and transcytosis, delivering cholecalciferol directly into the lymphatic system and systemic circulation.[15][2][1]

  3. Stability: Liposomes resist destabilization by gastric acid, mechanical stress, and digestive enzymes. Only bile salts in the intestine gradually solubilize them into smaller mixed micelles, accelerating absorption.[2][1]

Clinical Evidence: A crossover trial in 18 healthy volunteers (10,000 IU dose, fasted state) demonstrated that liposomal vitamin D3 produced: - 4-fold greater AUC (area under curve) for serum calcidiol over 30 days (8.5 vs. 1.69 day·ng/L)[2] - Rapid onset: Significant calcidiol elevation within 1-5 hours post-dose (absorption rate 4.01×10⁻⁴ /min vs. 7.03×10⁻⁵ /min for oil; p<0.05)[1][2] - Deficiency-dependent response: Effects most pronounced in individuals with severe vitamin D deficiency (initial 25(OH)D <12 ng/mL), where liposomal absorption was ~100-fold more efficient than oil[1]

Isothermal titration calorimetry and molecular dynamics simulations confirmed that cholecalciferol remains sequestered within liposomal bilayers (ΔH ~0.2-0.45 kJ/mol when mixed with albumin or empty liposomes), indicating absorption depends entirely on the fate of the delivery vehicle rather than spontaneous vitamin release.[1]

Practical Implications: - Food-independent absorption (liposomes remain stable regardless of gastric contents)[2] - Suitable for individuals with normal hepatic and intestinal function - May be preferable for rapid repletion in deficiency states - Available as over-the-counter supplements with variable quality; look for products with documented particle size (<200 nm) and stability data

Calcidiol: Bypassing Hepatic Conversion

Calcidiol is 25-hydroxyvitamin D3, the first metabolite in the vitamin D activation pathway and the biomarker used clinically to assess vitamin D status.[5][16][17]

Pharmacokinetic Advantages:

  1. Hepatic Independence: Calcidiol bypasses the rate-limiting CYP2R1-mediated hepatic 25-hydroxylation step required for cholecalciferol. This confers critical advantages in patients with:[17][5]

    • Chronic liver disease (cirrhosis, hepatitis, NAFLD)[18][19][20]
    • Hepatic CYP450 dysfunction
    • Malabsorption syndromes affecting fat-soluble vitamin processing[20][17]

  2. Hydrophilicity: Calcidiol is more water-soluble than cholecalciferol (less reliant on bile acids for solubilization), preserving absorption even with cholestatic liver disease or bile insufficiency.[5][17][20]

  3. Linear Dose-Response: Unlike cholecalciferol, which exhibits variable efficacy depending on baseline 25(OH)D levels, calcidiol produces predictable, consistent serum 25(OH)D increases irrespective of starting status.[3][7][5]

  4. Reduced Adipose Sequestration: Calcidiol's lower lipophilicity makes it less prone to sequestration in adipose tissue compared to cholecalciferol, an important consideration in obesity where vitamin D bioavailability is compromised.[21][22][17]

Clinical Efficacy: Multiple randomized controlled trials demonstrate calcidiol's superiority over equimolar cholecalciferol:[4][7][8][23][3]

  • Speed: Achieves target 25(OH)D >30 ng/mL within 4 weeks (87.5% of patients) vs. 4 months for cholecalciferol (23.1%; p<0.001)[3]
  • Potency: Meta-analysis of 17 studies (1,575 participants) confirms 3.2-8-fold greater potency on a weight basis. For example, 20 μg/day calcidiol raised 25(OH)D more effectively than 60 μg/day cholecalciferol (final levels 42.4±15.9 vs. 29.6±4.1 ng/mL; p=0.007)[23][24][25][4][5]
  • Consistency: Monthly calcidiol (266 μg) produced stable, sustained 25(OH)D elevations with no breakthrough deficiency, while cholecalciferol showed greater intra-individual variability[7]

Clinical Contexts Favoring Calcidiol:

Condition Mechanism Evidence Level
Obesity Reduced adipose sequestration; calcidiol combined with hypocaloric diet reduced visceral adiposity indices (LAP, NVAI) vs. cholecalciferol[21][22] RCT (84 patients)[21]
Chronic kidney disease (CKD) stages 3-4 FDA-approved Rayaldee® suppresses PTH without excess hypercalcemia/hyperphosphatemia vs. VDR activators[26][9][10] Phase III trials[9]
Chronic liver disease Bypasses impaired hepatic hydroxylation; preferred in cirrhosis, cholestasis[18][19][20][27] Expert consensus[20][27]
Malabsorption (celiac, IBD, bariatric surgery) More hydrophilic; absorption relatively preserved[17][20][28] Case series[28]
Rapid correction needed Faster onset in acute settings (e.g., ICU, COVID-19)[29] Real-world evidence[29]

Safety and Tolerability

Both formulations demonstrate favorable safety profiles when appropriately dosed, though mechanisms of toxicity differ.

Liposomal Vitamin D3 Safety

  • Hypercalcemia risk: Equivalent to standard cholecalciferol; sustained daily intake >10,000 IU or serum 25(OH)D >80 ng/mL increases risk[30][31]
  • Liposomal encapsulation mitigates toxicity: Preclinical data suggest liposomes reduce inflammatory pathway activation and hypercalcemic toxicity at equivalent doses compared to free cholecalciferol[32][15]
  • Long-term safety: No serious adverse events reported in trials; generally recognized as safe (GRAS) for dietary use[2][1]
  • Quality variability: Consumer supplements lack regulatory oversight; efficacy depends on validated liposomal size/stability (look for third-party testing)[33]

Calcidiol Safety

  • Narrower therapeutic window: As a more potent metabolite, calcidiol requires careful dosing and monitoring[31][34][35]
  • Hypercalcemia: Observed in 1.1% of patients receiving 100 μg/week calcidiol over 52 weeks (only 1 patient >100 ng/mL, no toxicity). Extended-release formulation (Rayaldee®) minimizes spikes vs. immediate-release[9][10][34][36]
  • Contraindications: Pre-existing hypercalcemia (serum Ca >9.8 mg/dL) is absolute contraindication[37][9]
  • Drug interactions: Calcidiol may enhance digitalis toxicity via hypercalcemia; concurrent use requires close monitoring[38][39]
  • Pregnancy/lactation: Limited human data; use cautiously (FDA pregnancy category C for Rayaldee®)[40]

Comparative safety takeaway: Liposomal vitamin D3 carries standard cholecalciferol risks, while calcidiol demands greater clinical oversight due to higher potency and prescription status in therapeutic settings.

Efficacy in Special Populations

Obesity

Calcidiol demonstrates superior outcomes: - RCT in 84 obese patients (BMI >30) combining Mediterranean hypocaloric diet with vitamin D showed calcidiol group achieved: - +20 ng/mL increase in 25(OH)D (vs. +12 ng/mL for cholecalciferol) - -7.8 kg weight loss (vs. -5.2 kg) - Significant reduction in visceral adiposity indices (p<0.05)[22][21] - Mechanism: Reduced adipose sequestration allows more circulating calcidiol to reach target tissues[41][17][21]

Liposomal vitamin D3: No head-to-head trials in obesity. Theoretical advantage from enhanced absorption, but cholecalciferol still subject to adipose storage. Likely inferior to calcidiol in this population.

Chronic Kidney Disease

Calcidiol is evidence-based standard: - FDA-approved Rayaldee® (extended-release calcidiol 30-60 μg/day) for stage 3-4 CKD with secondary hyperparathyroidism (SHPT)[10][9] - Phase III trials: ≥30% PTH reduction in 33% of calcidiol-treated patients vs. 8% placebo at 26 weeks; 80% corrected vitamin D insufficiency[9] - Advantages over active vitamin D analogs (calcitriol, paricalcitol): Lower hypercalcemia/hyperphosphatemia risk; over VDRAs: physiologic repletion[26][10]

Liposomal vitamin D3: No specific CKD trials. Not suitable for advanced CKD (stages 4-5) where renal 1α-hydroxylase is impaired, limiting conversion of 25(OH)D to active 1,25(OH)₂D.

Liver Disease

Calcidiol is preferred: - Impaired hepatic 25-hydroxylation in cirrhosis, hepatitis C, NAFLD reduces cholecalciferol efficacy[19][18][20] - Calcidiol bypasses this defect; expert consensus recommends it for severe liver disease (Child-Pugh B/C)[27][20] - Evidence: Vitamin D supplementation (including calcidiol) reduces ALT, AST, γ-GT, and HOMA-IR in chronic liver disease meta-analysis[19]

Liposomal vitamin D3: Inadequate in severe hepatic impairment; may suffice in mild disease (Child-Pugh A) where residual hydroxylase activity remains.

Malabsorption Syndromes

Calcidiol has theoretical and clinical advantages: - Celiac disease, IBD, bariatric surgery: Calcidiol's hydrophilicity preserves absorption when fat malabsorption is present[28][17][20] - Case report: Woman with obesity, chronic liver disease, and malabsorption achieved rapid 25(OH)D elevation with calcidiol after cholecalciferol failure[42][43]

Liposomal vitamin D3: May offer some benefit via enhanced penetration across disrupted intestinal mucosa, but lacks direct evidence in malabsorption. Inferior to calcidiol when combined hepatic and intestinal dysfunction exists.

Cost-Effectiveness and Access

Liposomal Vitamin D3

  • Over-the-counter availability: Widely accessible as dietary supplement (no prescription required)
  • Cost: $15-$30 for 30-120 servings (variable potency: 2,000-50,000 IU/dose)[11][12][13][44][45][46]
  • Quality concerns: Not FDA-regulated; efficacy depends on manufacturer's liposomal technology validation. Reputable brands provide particle size characterization and stability testing[46][33]

Calcidiol

  • Prescription required (in U.S. for therapeutic use; OTC in some European countries)[10][9]
  • Cost: Rayaldee® ~$1,180/month for 30×30 μg capsules; GoodRx coupon reduces to ~$917[14]
  • Generic/compounded alternatives: Lower-cost calcidiol available in some countries (e.g., Spain, Chile), typically $10-50/month for OTC formulations[29][47]
  • Insurance coverage: Often restricted to FDA-approved indication (CKD-related SHPT); denial common for off-label use

Cost-effectiveness analysis: For general vitamin D supplementation in healthy individuals, liposomal vitamin D3 offers better value. For clinical conditions (obesity, CKD, liver disease), calcidiol's superior efficacy may justify higher costs despite lack of widespread insurance coverage for non-CKD indications.

Dosing and Administration

Liposomal Vitamin D3

  • General supplementation: 2,000-5,000 IU daily (50-125 μg cholecalciferol)[45][48][46]
  • Deficiency correction: 10,000-50,000 IU daily or weekly; monitor 25(OH)D after 8-12 weeks[12]
  • Administration: Oral liquid, softgel, or capsule; can be taken with or without food (liposomal stability preserves absorption)[46][2]
  • Target: Serum 25(OH)D 30-50 ng/mL (75-125 nmol/L)[49]

Calcidiol

  • Therapeutic (CKD-SHPT): Rayaldee® 30 μg/day at bedtime initially; increase to 60 μg after 3 months if PTH remains elevated[50][37][9][10]
  • Nutritional repletion (European protocols): 10-20 μg/day (equivalent to ~40-80 μg cholecalciferol)[24][51][5]
  • Rapid correction: 266 μg fortnightly or monthly until 25(OH)D >30 ng/mL, then maintenance[52][3]
  • Monitoring: Serum calcium, phosphorus, PTH, and 25(OH)D every 3 months[37][9]
  • Target: 25(OH)D 30-100 ng/mL (avoid >150 ng/mL)[34][31]
  • Food effect: High-fat meals increase calcidiol absorption 3.5-5-fold; Rayaldee® should be taken at bedtime (fasting) to minimize variability[53][50]

Key distinction: Calcidiol requires ~3× lower microgram dosing than cholecalciferol for equivalent 25(OH)D elevation, reflecting its higher potency.[24][5]

Clinical Decision Framework

Clinical Scenario Preferred Formulation Rationale
Healthy adults, general supplementation Liposomal vitamin D3 or standard cholecalciferol Cost-effective; no special requirements[49][16]
Vitamin D deficiency (<20 ng/mL), normal health Liposomal vitamin D3 Rapid correction (hours-days vs. weeks)[1][2]
Obesity (BMI >30) Calcidiol Reduces visceral fat, overcomes adipose sequestration[21][22][41]
CKD stages 3-4 with SHPT Calcidiol (Rayaldee®) FDA-approved; evidence-based for PTH suppression[26][9][10]
CKD stage 5 (dialysis) Active vitamin D (calcitriol) or calcimimetics Calcidiol/cholecalciferol insufficient due to impaired renal 1α-hydroxylase[54][9]
Chronic liver disease (cirrhosis) Calcidiol Bypasses hepatic hydroxylation defect[18][19][20][27]
Malabsorption (celiac, IBD, bariatric) Calcidiol Better absorption when fat malabsorption present[17][20][28]
Acute/ICU settings requiring rapid repletion Calcidiol (if available) Fastest onset (days)[29]
Pregnancy/lactation Standard cholecalciferol (avoid calcidiol unless prescribed) Limited safety data for calcidiol[40]
Cost-sensitive, no insurance Liposomal vitamin D3 OTC access, lower price[11][12][14]

Evidence Gaps and Future Directions

Despite robust mechanistic and clinical data, several knowledge gaps persist:

  1. Head-to-head trials: No published RCTs directly comparing liposomal vitamin D3 to calcidiol in identical populations (e.g., obesity, deficiency correction).

  2. Long-term outcomes: Most liposomal vitamin D3 trials assess acute pharmacokinetics (hours to weeks). Long-term (>1 year) efficacy and safety data are limited compared to extensive calcidiol literature.[7][34][1][2]

  3. Liposomal quality standardization: Lack of regulatory oversight means consumer liposomal products vary widely in particle size, encapsulation efficiency, and stability. Independent validation studies are needed.[33]

  4. Calcidiol for non-CKD indications: While mechanistically justified and supported by RCTs, calcidiol lacks FDA approval for obesity, liver disease, or general deficiency in the U.S., limiting insurance coverage and clinical adoption.[9]

  5. Pediatric data: Both formulations lack extensive pediatric safety/efficacy studies.

  6. Cardiovascular and extraskeletal outcomes: Whether either formulation confers advantages for cardiovascular disease, immune function, or cancer prevention beyond standard cholecalciferol remains unproven.[26][49]

Conclusions

Liposomal vitamin D3 and calcidiol each address distinct limitations of conventional cholecalciferol supplementation through fundamentally different mechanisms. Liposomal technology enhances cholecalciferol bioavailability via advanced delivery, achieving 4-5-fold greater absorption and rapid onset—ideal for healthy individuals seeking efficient deficiency correction. Calcidiol, as a pre-activated metabolite, bypasses hepatic conversion with 3-8-fold higher potency, making it the evidence-based choice for patients with obesity, chronic kidney disease (stages 3-4), liver dysfunction, or malabsorption.

Practical Recommendations:

  • For most individuals: Liposomal vitamin D3 (2,000-5,000 IU/day) offers excellent cost-effectiveness and convenience for maintenance supplementation, provided the product has validated liposomal characteristics.
  • For complex medical conditions (CKD, cirrhosis, obesity, malabsorption): Calcidiol is superior despite higher cost and prescription requirements, particularly when rapid correction or hepatic/intestinal pathology exists.
  • Monitoring: Regardless of formulation, measure serum 25(OH)D after 8-12 weeks to confirm adequacy (target 30-50 ng/mL) and assess calcium/phosphorus to exclude toxicity.

The choice between liposomal vitamin D3 and calcidiol should be individualized based on clinical context, cost considerations, and regulatory access, recognizing that both represent significant advancements beyond traditional oil-based cholecalciferol for optimizing vitamin D status.

References

Citations correspond to search result IDs throughout the analysis. Full references available upon request.

[1] https://pmc.ncbi.nlm.nih.gov/articles/PMC8957331/

[2] https://pmc.ncbi.nlm.nih.gov/articles/PMC10052077/

[3] https://academic.oup.com/jbmr/article/36/10/1967/7516555

[4] https://pubmed.ncbi.nlm.nih.gov/39385006/

[5] https://pmc.ncbi.nlm.nih.gov/articles/PMC9979899/

[6] https://pubmed.ncbi.nlm.nih.gov/35346834/

[7] https://academic.oup.com/jbmr/article/38/4/471/7499956

[8] https://pubmed.ncbi.nlm.nih.gov/34101900/

[9] https://pmc.ncbi.nlm.nih.gov/articles/PMC5083074/

[10] https://pubmed.ncbi.nlm.nih.gov/30058895/

[11] https://www.kalvitamins.com/products/liposomal-d3

[12] https://upnourishbrand.com/products/liposomal-vitamin-d3-50000-iu-k-1000-mcg

[13] https://goldmanlaboratories.com/products/liposomal-vitamin-d-complex-30-caps

[14] https://www.goodrx.com/rayaldee/what-is

[15] https://pmc.ncbi.nlm.nih.gov/articles/PMC11807986/

[16] https://ods.od.nih.gov/factsheets/VitaminD-HealthProfessional/

[17] https://pubmed.ncbi.nlm.nih.gov/36862209/

[18] https://pmc.ncbi.nlm.nih.gov/articles/PMC5946281/

[19] https://academic.oup.com/nutritionreviews/article/83/11/2043/8196857

[20] https://www.sochob.cl/web1/wp-content/uploads/2025/03/Vitamin-D-Supplementation-Practical-Advice-in-Different-Clinical-Settings.pdf

[21] https://pmc.ncbi.nlm.nih.gov/articles/PMC12672259/

[22] https://www.frontiersin.org/journals/nutrition/articles/10.3389/fnut.2025.1676668/full

[23] https://pmc.ncbi.nlm.nih.gov/articles/PMC8597097/

[24] https://pubmed.ncbi.nlm.nih.gov/29713796/

[25] https://academic.oup.com/jcem/article/102/4/1133/2982842

[26] https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2025.1643415/full

[27] https://pubmed.ncbi.nlm.nih.gov/32486496/

[28] https://academic.oup.com/jes/article/1/8/1079/3964567

[29] https://www.nature.com/articles/s41598-021-02701-5

[30] https://www.sciencedirect.com/science/article/pii/S0002916522043763

[31] https://pmc.ncbi.nlm.nih.gov/articles/PMC5045493/

[32] https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1529007/full

[33] https://plantacorp.com/liposomal-bioavailability-studies-explained/

[34] https://pmc.ncbi.nlm.nih.gov/articles/PMC12072334/

[35] https://synapse.patsnap.com/article/what-are-the-side-effects-of-calcifediol

[36] https://rayaldee.com/wp-content/themes/rayaldee/pdfs/hcp/erc-for-shpt-in-stage-3-4-ckd.pdf

[37] https://pdf.hres.ca/dpd_pm/00069537.PDF

[38] https://www.rxlist.com/calcifediol/generic-drug.htm

[39] https://reference.medscape.com/drug/rayaldee-calcifediol-1000075

[40] https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208010Orig1s013lbl.pdf

[41] https://academic.oup.com/jcem/article/102/7/2564/2982841

[42] https://pubmed.ncbi.nlm.nih.gov/41123175/

[43] https://www.scielo.br/j/aem/a/69kc7xFYwDsmwzcWZ8979SJ/

[44] https://www.theofficehealth.com/products/liposomal-vitamin-d3-k2

[45] https://1stphorm.com/products/liposomal-vitamin-d3

[46] https://www.quicksilverscientific.com/products/d3k2

[47] https://pmc.ncbi.nlm.nih.gov/articles/PMC6624911/

[48] https://centenarianroad.com/en/products/vitamin-d3-and-k2-capsules

[49] https://academic.oup.com/edrv/article/45/5/625/7659127

[50] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208010Orig1s000ClinPharmR.pdf

[51] https://www.sciencedirect.com/science/article/pii/S0261561417301206

[52] https://www.sciencedirect.com/science/article/abs/pii/S0960076023000031

[53] https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208010s000lbl.pdf

[54] https://davita.com/diet-nutrition/articles/vitamin-d-and-chronic-kidney-disease/

[55] https://pdfs.semanticscholar.org/f381/03dcecd80d70b560cddd7b4f008a4e37c088.pdf

[56] https://www.sciencedirect.com/science/article/abs/pii/S1549963422000387

[57] https://www.kidney.org/sites/default/files/Vitamin-D-Supplementation-Patients-With-CKD.pdf

[58] https://www.sciencedirect.com/science/article/abs/pii/S0939641116308530

[59] https://clinicaltrials.gov/study/NCT06010121

[60] https://clinicaltrials.gov/study/NCT02868827

[61] https://novoma.com/en/blogs/articles/meilleure-vitamine-d3

[62] https://dwatrolaboratories.com/en/liposomal-vitamin-d-advantages-over-traditional-forms-and-how-to-use-it/

[63] https://www.nature.com/articles/s41538-025-00460-5

[64] https://www.creighton.edu/medicine/research/research-centers-and-institutes/osteoporosis-research-center/vitamin-d-immunity

[65] https://www.dynamed.com/drug-review/vitamin-d-intake-and-supplementation-for-adults/PlatformBrowse

[66] https://liposomal.it/en/liposomal-product/liposomal-vitamin-d/

[67] https://www.amritanutrition.co.uk/blogs/news/benefits-of-calcifediol-vitamin-d-for-health-and-fitness

[68] https://www.sciencedirect.com/topics/neuroscience/calcifediol

[69] https://www.sciencedirect.com/science/article/pii/S0168827812003601

[70] https://www.endocrine-abstracts.org/ea/0070/ea0070oc2.6

[71] https://www.mayoclinic.org/drugs-supplements/calcifediol-oral-route/description/drg-20312274

[72] https://www.sciencedirect.com/science/article/pii/S0753332218367039

[73] https://www.dsm-firmenich.com/en/businesses/health-nutrition-care/news/talking-nutrition/calcifediol-supplements-for-mobility-health0.html

[74] https://www.vitamind-journal.it/en/wp-content/uploads/2023/11/03GiustiEN-1.pdf

[75] https://www.webmd.com/vitamins/ai/ingredientmono-929/vitamin-d

[76] https://en.wikipedia.org/wiki/Vitamin_D

[77] https://pubmed.ncbi.nlm.nih.gov/12520541/

[78] https://pmc.ncbi.nlm.nih.gov/articles/PMC3405161/

[79] https://academic.oup.com/jbmrplus/article/5/12/e10554/7479599

[80] https://www.sciencedirect.com/science/article/pii/S1818087613000135

[81] https://www.elsevier.es/en-revista-annals-hepatology-16-articulo-an-argument-for-vitamin-d-S1665268119310543

[82] https://www.sciencedirect.com/science/article/pii/S0002916523167050

[83] https://spj.science.org/doi/10.1186/s40824-016-0083-1

[84] https://www.wbcil.com/blog/how-west-bengal-chemical-industries-limited-wbcil-is-pioneering-liposomal-nutraceuticals-for-lymphatic-activation/

[85] https://www.creative-biolabs.com/targeted-delivery/vitamins-in-drug-delivery.htm

[86] https://clinicaltrials.gov/study/NCT06585995

[87] https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208010Orig1s000PharmR.pdf

[88] https://pubmed.ncbi.nlm.nih.gov/23664686/

[89] https://www.sciencedirect.com/science/article/abs/pii/B9780323913386000239

[90] https://healthy.kaiserpermanente.org/health-wellness/drug-encyclopedia/drug.calcifediol-er-30-mcg-capsule-24-hr-extended-release.591025

[91] https://www.sciencedirect.com/topics/medicine-and-dentistry/calcifediol

[92] https://clinicaltrials.gov/study/NCT01503216

[93] https://www.isrctn.com/ISRCTN39055102

[94] https://www.walmart.com/c/kp/liposomal-d3-k2-benefits

[95] https://www.sciencedirect.com/science/article/pii/S026156142500072X

[96] https://zooki.com/en-us/products/liposomal-vitamin-d-liquid

[97] https://rayaldee.com/wp-content/themes/rayaldee/pdfs/rayaldee-pi.pdf

[98] https://www.apexbt.com/calcifediol-monohydrate.html

[99] https://www.sciencedirect.com/science/article/pii/S0753332218351242

[100] https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2800490

[101] https://pmc.ncbi.nlm.nih.gov/articles/PMC2878736/

[102] https://www.nature.com/articles/s41598-024-58154-z

[103] https://pmc.ncbi.nlm.nih.gov/articles/PMC4440015/

[104] https://pmc.ncbi.nlm.nih.gov/articles/PMC9545200/

[105] https://www.youtube.com/watch?v=oFFAIe_38Ok

[106] https://onlinelibrary.wiley.com/doi/10.1111/nbu.12369

[107] https://www.kidney.org/kidney-topics/vitamins-chronic-kidney-disease

[108] https://pmc.ncbi.nlm.nih.gov/articles/PMC10347199/

[109] https://www.semanticscholar.org/paper/Novel-Approach-for-the-Approximation-of-Vitamin-D3-%C5%BBurek-Przyby%C5%82o/bf38777784dee10561b8d4ec2d147e5fa3ccab90

[110] https://www.clinicaltrials.gov/study/NCT05209425

[111] https://www.sciencedirect.com/science/article/pii/S1756464625004451

[112] https://clinicaltrials.gov/study/NCT02333682

[113] https://en.wikipedia.org/wiki/Calcifediol

[114] https://www.isrctn.com/pdf/39055102

[115] https://medlineplus.gov/druginfo/meds/a682335.html

[116] https://www.medcentral.com/drugs/monograph/7448-382335/calcitriol-oral

[117] https://go.drugbank.com/drugs/DB00146

[118] https://www.ncbi.nlm.nih.gov/books/NBK526025/

[119] https://go.drugbank.com/drugs/DB00136

[120] https://www.accessdata.fda.gov/drugsatfda_docs/label/1998/21068lbl.pdf

[121] https://rayaldee.com/hcp/about-rayaldee/

[122] https://www.opko.com/investors/news-events/press-releases/detail/268/fda-approves-new-drug-application-for-rayaldee-to-treat-secondary-hyperparathyroidism-associated-with-vitamin-d-insufficiency-in-stage-3-4-chronic-kidney-disease

[123] https://www.walmart.com/ip/Liposomal-Vitamin-D3-5000-IU-Softgel-with-Organic-Coconut-Oil-1-Year-Supply-Vitamin-D-Supplement-365-Softgels/673907815

Asked about the Kinetics of the two forms

Liposomal vitamin D3 (cholecalciferol)

  • In a human trial, liposomal D3 produced a measurable increase in serum 25(OH)D within the first few hours after a single dose, while the oily form showed essentially no change in that same time window.[1][2]
  • The 25(OH)D curve continues to rise and typically peaks around 3 days after a cholecalciferol dose (liposomal or not), but the onset of the rise with liposomal D3 is clearly in the hour range.[2][1]

So for liposomal D3, onset = hours; peak effect = a few days.

Calcidiol (25(OH)D3)

  • Calcidiol starts to raise serum 25(OH)D within hours as well, but most clinical papers describe its clinically relevant rise and target attainment over days to weeks (for example, reaching target 25(OH)D within a few days with high-dose calcidiol, vs weeks with cholecalciferol).[3][4]
  • Pharmacokinetic studies consistently describe calcidiol as faster and more potent than standard vitamin D3 for raising 25(OH)D, but they report the main comparisons over days to weeks, not minute‑by‑minute onset.[4][5][6]

So for calcidiol, onset is also hours, but most “speed” claims are about how fast it reaches desired levels over days compared with ordinary D3.

How to reconcile the confusion

  • Both liposomal D3 and calcidiol begin to change 25(OH)D within hours. Liposomal data make this very explicit.[1][2]
  • Calcidiol is faster than standard (non‑liposomal) D3 in getting you to a new steady 25(OH)D level over days–weeks, but that does not mean its onset is slower than liposomal D3.[5][7][4]
  • The phrase “Rapid (hours)” vs “Very rapid (days)” was poorly chosen; “very rapid” should have been reserved for faster attainment of target levels over days vs weeks, not for onset relative to liposomal D3.

A clearer summary:

  • Onset of detectable 25(OH)D increase

    • Liposomal D3: hours.[2][1]
    • Calcidiol: hours (but most clinical reporting focuses on day‑scale effects).[3][4]

  • Time to reach target 25(OH)D range in practice

    • Liposomal D3: days–weeks (faster than oily D3).[1][2]
    • Calcidiol: generally fewer days–weeks than equivalent D3 doses; often clearly superior over 2–12 weeks.[6][4][5]

So if you are thinking strictly in terms of onset, liposomal D3 is not slower than calcidiol; both act on an hour scale. The real advantage of calcidiol is potency and reliability over days to weeks, especially in difficult clinical settings, not a faster “first rise” than a good liposomal formulation.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20

Related in VitaminDWiki